Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Time to clinical recovery 20% Improvement Relative Risk Time to clinical reco.. (b) 27% Median time to PCR- 71% Median time to PCR- (b) 64% HCQ  Chen et al.  LATE TREATMENT  RCT Is late treatment with HCQ beneficial for COVID-19? RCT 48 patients in China (February - March 2020) Faster viral clearance with HCQ (p=0.00044) c19hcq.org Chen et al., medRxiv, June 2020 Favors HCQ Favors control

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

Chen et al., medRxiv, doi:10.1101/2020.06.19.20136093
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19hcq.org
RCT 48 hospitalized patients in China showing faster clinical recovery and viral clearance with CQ/HCQ.
time to clinical recovery, 20.0% lower, relative time 0.80, p = 0.51, treatment median 6.0 IQR 5.0 n=18, control median 7.5 IQR 11.25 n=12, HCQ.
time to clinical recovery, 26.7% lower, relative time 0.73, p = 0.36, treatment median 5.5 IQR 4.25 n=18, control median 7.5 IQR 11.25 n=12, CQ.
median time to PCR-, 71.4% lower, relative time 0.29, p < 0.001, treatment median 2.0 IQR 1.5 n=18, control median 7.0 IQR 7.0 n=12, HCQ.
median time to PCR-, 64.3% lower, relative time 0.36, p = 0.001, treatment median 2.5 IQR 1.8 n=18, control median 7.0 IQR 7.0 n=12, CQ.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chen et al., 22 Jun 2020, Randomized Controlled Trial, China, preprint, 19 authors, study period 18 February, 2020 - 30 March, 2020, dosage 200mg bid days 1-10.
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.19.20136093; this version posted June 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study Lan Chen1, Zhen-Yu Zhang1, Jian-Guo Fu1, Zhi-Peng Feng1, Su-Zhen Zhang1, Qiu-Ying Han1, Xiao-Bin Zhang1, Xiong Xiao2, Hui-Min Chen3, Li-Long Liu4, Xian-Li Chen5, Yu-Pei Lan6, De-Jin Zhong7, Lan Hu8, Jun-Hui Wang8, Xing-Hua Yu1, Dan-Yang She9*, Yong-Hong Zhu10* and Zhen-Yu Yin1* 1 Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China; 2 Department of Respiratory, Xiamen Branch of Zhongshan Hospital Affiliated to Fudan University, Xiamen, Fujian, China; 3 Department of Intensive Care Unit, Xiamen Third Hospital, Xiamen, Fujian, China; 4 Department of Infectious Disease, Hongai Hospital, Xiamen, Fujian, China; 5 Department of Infectious Disease, Xiang'an Hospital Affiliated to Xiamen University, Xiamen, Fujian, China; 6 General Office, Xiamen Haicang Hospital, Xiamen, Fujian, China; 7 Department of Gastroenterology, Xiamen Changgen Hospital, Xiamen, Fujian, China; 8 Optics Valley Branch of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Wuhan, Hubei, China. 9 Department of Pulmonary and Critical Care Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China 10 Early Clinical Development of Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center, Shanghai 201203, China * Corresponding author: Zhen-Yu Yin Zhongshan Hospital, Xiamen University, Department of Hepatobiliary Surgery 201, Hubin South Road, Siming qu Xiamen, Fujian 361004, China E-mail: yinzy@xmu.edu.cn NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.06.19.20136093; this version posted June 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Dan-Yang She* Department of Pulmonary and Critical Care Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China E-mail: dysheh@163.com Yong-Hong Zhu* Early Clinical Development of Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center, Shanghai 201203, China E-mail: yonghong.zhu.yz2@roche.com Key words: coronavirus disease 2019, COVID-19, SARS-CoV-2, chloroquine, hydroxychloroquine, time to clinical recovery RUNNING TITLE: (hydroxy)chloroquine in treating COVID-19 CONFLICT OF INTEREST The authors declare no conflict of interest regarding the contents of this article. FUNDING This study was funded by the Medical and Health Key project of Xiamen (3502Z20191106), which is a project of the Xiamen Science and Technology Bureau (3502Z20194016). Target journal: Clinical and Translational Science Word count: 5795 Abstract: 237 (max 250) Text: 3977 (max 4000) Tables/figures: 3+2 (max 7) References:22 (max 50) medRxiv preprint doi: https://doi.org/10.1101/2020.06.19.20136093; this..
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit